Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals

Abstract

Objective: To evaluate the long-term effects of different boosted protease inhibitors (bPIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based antiretroviral regimens on lipid levels in HIV seropositive individuals who have not received lipid-lowering agents.

Methods: Data consisted of 595 patients participating in the population-based Athens Multicenter Cohort Study who were consistently followed up during 1996–2008.

Results: In naïve patients, lipid parameters increased sharply during the first 3 months of antiretroviral therapy and reached a plateau level approximately 6–9 months after therapy initiation. The plateau levels remained almost stable for up to 3·5 years. In general, bPIs exerted a more pronounced effect compared to NNRTIs.

Conclusions: The administration of PI- or NNRTI-based regimens especially in naïve but also in unboosted PI experienced patients provoked a sharp increase in lipid levels that remained stable in higher levels for more than 3 years.

Keywords:

• HIV
• Antiretrovirals
• Lipid levels

AMACS consists of the following members:

Steering Committee: Antoniadou A., Chrysos G., Daikos G., Gargalianos-Kakolyris P., Gogos H.A., Katsarou O., Kordossis T., Lazanas M., Nikolaidis P., Panos G., Paparizos V., Paraskevis D., Sambatakou H., Skoutelis A., and Touloumi G. (Chair).

Coordinating Center: Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Greece (Touloumi G., Pantazis N., Bakoyannis G., Vourli G., and Gioukari V.)

Participating Centers: Fourth Department of Internal Medicine, Athens Medical School, Attikon University Hospital (Antoniadou A., Papadopoulos A., and Petrikkos G.); Infectious Disease Unit, ‘Tzaneio’ General Hospital of Pireaus (Chrysos G., Paraskeva D., and Hatziastros P.); First Department of Propedeutic Medicine, Athens University, Medical School ‘Laikon’ General Hopsital (Daikos G. and Psichogiou M.); First Department of Medicine, Infectious Diseases Unit, ‘G. Gennimatas’ Athens General Hospital (Gargalianos-Kakolyris P. and Xylomenos G.); First Department of Internal Medicine, Infectious Diseases Section, Patras University Hospital (Gogos H.A., Maragos M.N., and Panos G.); Haemophilia Centre, Second Blood Transfusion Centre, ‘Laikon’ Athens General Hospital (Katsarou O., Kouramba A., and Ioannidou P.); AIDS Unit, Department of Pathophysiology, ‘Laikon’ Athens General Hospital and Athens University, Medical School (Kordossis T. and Kontos A.); Infectious Diseases Unit, Red Cross General Hospital of Athens (Lazanas M., Chini M., and Tsogas N.); First Department of Internal Medicine, Infectious Diseases Devision, AHEPA University Hospital, Aristotle University HIV Unit (Nikolaidis P., Kolaras P., and Metallidis S.); Second Internal Medicine Clinic, First IKA Hospital (Panos G. and Haratsis G.); AIDS Unit, Clinic of Venereologic & Dermatologic Diseases, Athens University, Medical School, Syngros Hospital (Paparizos V., Leuow K., and Kourkounti S.); HIV Unit, Second Department of Internal Medicine, Athens University, Medical School, Hippokration General Hospital (Sambatakou H., and Mariolis I.); Infectious Diseases & HIV Division, Department of Internal Medicine, Evaggelismos Athens General Hospital (Skoutelis A., Papastamopoulos V., and Baraboutis I.).